



CIN No. : L51909GJ2014PLC078227

GST No. : 24AAECT8906D1ZG

**TRIDENT LIFELINE LIMITED**

(Formerly Trident Lifeline Private Limited)

**Date: 18.03.2026**

<b>BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai - 400001.</b>	<b>Stock ID: TLL Scrip Code: 543616</b>
---	---

Dear Sir/Ma'am,

**Sub: Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Ma'am,

We wish to inform to the Exchange that **TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421)**, a subsidiary company has made Private Placement of equity shares to other shareholders. Pursuant to the above allotment to other shareholders, the shareholding of Trident Lifeline Limited in Trident Mediquip Limited stands at 57.10%.

Further informed to the Exchange that Trident Lifeline Limited has made further Investment by acquiring an additional equity stake of 2.67% of TRIDENT MEDIQUIP LIMITED (TML) (CIN: U33309GJ2019PLC110421), a subsidiary company from existing shareholders of the Company. Pursuant to the above, the shareholding of the company in Trident Mediquip Limited has increased from 57.10% to 59.77%.

We enclosed herewith the details required under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 as **Annexure - A**.

Thanking You.

Yours faithfully,

**FOR TRIDENT LIFELINE LIMITED**

**NIKITA SHARMA**

**COMPANY SECRETARY AND COMPLIANCE OFFICER**

**M. NO.: A60595**

**TRIDENT LIFELINE LIMITED**

(Formerly Trident Lifeline Private Limited)

**Annexure-A**

**Information under Regulation 30 of SEBI (LODR) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1	Name of the target entity, details in brief such as size, turnover etc.	<p><b>TRIDENT MEDIQUIP LIMITED</b> (CIN: U33309GJ2019PLC110421) Company incorporated under the provisions of the Companies Act, 2013, having its Registered Office in Surat, Gujarat</p> <p><b>Capital Details:</b>  <b>Authorized Share Capital:</b> Rs. 10,00,00,000/- divided into 1,00,00,000 Equity Shares of Rs.10/- each</p> <p><b>Paid-up Share Capital:</b> Rs. 9,81,58,000/- divided into 98,15,800 Equity Shares of Rs.10/- each</p> <p><b>Turnover:</b> 21.29 Cr</p>
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	<p><b>Yes, TRIDENT MEDIQUIP LIMITED</b>, Subsidiary of Trident Lifeline Limited, therefore is a related party. Also Mr. Amit Bhupendra Halvawala and Mr. Chetan Chandrakant Jariwala (director's Relative of Rupaben Jariwala) are member cum Director, Mr. Hardik Jigishkumar Desai members and all of above are part of promoters/promoter group/board of acquiring Company i.e being Trident Lifeline Limited (The Company), have an interest in the entity being acquired (TML).</p> <p>The transaction is being undertaken on an arm's length basis.</p>
3	Industry to which the entity being acquired belongs	Pharmaceuticals Industry
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	TRIDENT MEDIQUIP LIMITED is a subsidiary of the company. In order to further allotment of shares to other shareholders and increase of stake in TML, percentage of holding its stake in TML stands at 59.77%.

**TRIDENT LIFELINE LIMITED**

(Formerly Trident Lifeline Private Limited)

5	Brief details of any governmental or regulatory approvals required for the acquisition.	NA
6	Indicative time period for completion of the acquisition	NA
7	Consideration - whether cash consideration or share swap and details of the same;	NA
8	Cost of acquisition or the price at which the shares are acquired;	NA
9	Percentage of shareholding / control acquired and / or number of shares acquired;	<b>Pre holding:</b> 57.34% <b>Post holding:</b> 59.77%
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<b>Date of incorporation:</b> October 19, 2019 <b>Product/line of business:</b> Pharmaceuticals and Chemical Industry <b>Last 3 years' turnover:</b> Financial year 2022-23- 28.77 Cr. Financial year 2023-24- 20.58 Cr. Financial Year 2024-25- 21.29 Cr. <b>Presence of entity:</b> India